Sign in to view content

Twelve Month Safety and Efficacy Outcomes from a Phase 2 Study of APL-2 in Patients with Geographic Atrophy

David S. Boyer, MD

Video
Published 2017

Related

Preliminary Results from a First-in-human Phase I/II Gene Therapy Study (FOCUS) of Subretinally Delivered GT005, an Investigational AAV2 Vector, in Patients with Geographic Atrophy Secondary to Age-related Macular Degeneration
Jared S. Nielsen, MD, MBA
Updates from the Field
2022
Episode 199: Nov/Dec 2019 Retinal Physician Preview: New Pathways for Dry AMD
Jayanth Sridhar, MD
Member Podcasts
2019
Assessment of Progression of Geographic Atrophy in the FILLY Study
David R Lally, MD
On Demand Cases, Courses, and Papers
2020

Category: AMD-Neovascular

See more